BR112013000776A2 - método e formulação para tratamento de deficiência de ácido siálico - Google Patents

método e formulação para tratamento de deficiência de ácido siálico

Info

Publication number
BR112013000776A2
BR112013000776A2 BR112013000776A BR112013000776A BR112013000776A2 BR 112013000776 A2 BR112013000776 A2 BR 112013000776A2 BR 112013000776 A BR112013000776 A BR 112013000776A BR 112013000776 A BR112013000776 A BR 112013000776A BR 112013000776 A2 BR112013000776 A2 BR 112013000776A2
Authority
BR
Brazil
Prior art keywords
formulation
sialic acid
treatment
acid deficiency
deficiency
Prior art date
Application number
BR112013000776A
Other languages
English (en)
Portuguese (pt)
Inventor
Emil Kakkis
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of BR112013000776A2 publication Critical patent/BR112013000776A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013000776A 2010-07-13 2011-07-13 método e formulação para tratamento de deficiência de ácido siálico BR112013000776A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36399510P 2010-07-13 2010-07-13
PCT/US2011/043910 WO2012009474A1 (en) 2010-07-13 2011-07-13 Method and formulations for treating sialic acid deficiencies

Publications (1)

Publication Number Publication Date
BR112013000776A2 true BR112013000776A2 (pt) 2016-05-24

Family

ID=45469794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000776A BR112013000776A2 (pt) 2010-07-13 2011-07-13 método e formulação para tratamento de deficiência de ácido siálico

Country Status (10)

Country Link
US (4) US9511015B2 (https=)
EP (1) EP2593109A4 (https=)
JP (1) JP5777712B2 (https=)
KR (1) KR20140003380A (https=)
CN (2) CN108606956A (https=)
AU (1) AU2011279158B2 (https=)
BR (1) BR112013000776A2 (https=)
CA (1) CA2805222A1 (https=)
IL (1) IL224203B (https=)
WO (1) WO2012009474A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
KR20140003380A (ko) 2010-07-13 2014-01-09 울트라제닉스 파마수티컬 인코포레이티드 시알산 결함 치료용 방법들 및 제형들
HK1201067A1 (en) 2011-10-24 2015-08-21 罕见病药物研发公司 Sialic acid analogs
CA2862836A1 (en) * 2012-01-18 2013-07-25 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
WO2014031837A1 (en) * 2012-08-22 2014-02-27 The Regents Of The University Of California Compositions and methods for enhancing sialic acid levels in tissue
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US10385085B2 (en) 2015-09-14 2019-08-20 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11348013B2 (en) * 2017-10-31 2022-05-31 Vie Technologies Inc. Determining, encoding, and transmission of classification variables at end-device for remote monitoring
EP3486326A1 (en) 2017-11-21 2019-05-22 Jennewein Biotechnologie GmbH Method for the purification of n-acetylneuraminic acid from a fermentation broth
US20200371110A1 (en) * 2018-01-12 2020-11-26 The Wistar Institute Of Anatomy And Biology Methods for identifying and treating hiv persistence
CN110548012B (zh) * 2019-08-27 2022-05-13 嘉必优生物技术(武汉)股份有限公司 一种唾液酸片剂及其制备方法
CN121793948A (zh) * 2023-09-01 2026-04-03 豪夫迈·罗氏有限公司 用于制备半固体组合物的新颖方法及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
CA2215978A1 (en) 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6444649B1 (en) 1998-04-10 2002-09-03 Mitsubishi Chemical Corporation Solid dispersion containing sialic acid derivative
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
CA2549195A1 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
WO2006096161A1 (en) 2005-03-03 2006-09-14 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
EP2086515A2 (en) 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8410063B2 (en) * 2007-05-31 2013-04-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services N-acetyl mannosamine as a therapeutic agent
EP2192923A2 (en) * 2007-08-27 2010-06-09 Massachusetts Institute of Technology Bi-functional polymer-attached inhibitors of influenza virus
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
JP5626734B2 (ja) * 2009-05-15 2014-11-19 公益財団法人ヒューマンサイエンス振興財団 Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物
KR20140003380A (ko) 2010-07-13 2014-01-09 울트라제닉스 파마수티컬 인코포레이티드 시알산 결함 치료용 방법들 및 제형들
HK1201067A1 (en) 2011-10-24 2015-08-21 罕见病药物研发公司 Sialic acid analogs
CA2862836A1 (en) 2012-01-18 2013-07-25 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies

Also Published As

Publication number Publication date
JP5777712B2 (ja) 2015-09-09
US20130273160A1 (en) 2013-10-17
AU2011279158B2 (en) 2015-07-09
AU2011279158A1 (en) 2013-02-21
JP2013531041A (ja) 2013-08-01
EP2593109A4 (en) 2014-01-08
US9554987B2 (en) 2017-01-31
US20170157160A1 (en) 2017-06-08
US20170136051A1 (en) 2017-05-18
CN103370069A (zh) 2013-10-23
WO2012009474A1 (en) 2012-01-19
IL224203B (en) 2018-06-28
CA2805222A1 (en) 2012-01-19
KR20140003380A (ko) 2014-01-09
EP2593109A1 (en) 2013-05-22
US9511015B2 (en) 2016-12-06
CN108606956A (zh) 2018-10-02
US20130225513A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CR20120413A (es) Derivados de fumarato de ácido graso y sus usos
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
IN2014MN00948A (https=)
MX391043B (es) Formulaciones de anticuerpo y metodos.
MX2011013661A (es) Composiciones y metodos para el tratamiento de esclerosis multiple.
IN2014CN04634A (https=)
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
MX339198B (es) Composicion y metodo para tratar condiciones de la piel.
SG191068A1 (en) New form of administration of enkephalinase inhibitor
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
GT201400242A (es) "nuevos compuestos de pirazol"
BR112014017587A2 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico
BR112014009760A8 (pt) análogos de ácido siálico
MX2012007142A (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
CO7121334A2 (es) Formulaciones vesiculares
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
GT201200082A (es) Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.